Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Impact of Bigness in the Life Sciences: A View from Windhover's Start-Up Symposium

This article was originally published in Start Up

Executive Summary

Bigness is pervading the life sciences. Larger investments and larger partners are driving start-ups toward the largest markets to get ROI, encouraging in-licensing and rollup strategies. In devices, the trend towards size comes at the expense of developing niche markets. Meanwhile, biotechs are realizing they must integrate more and more technologies in parallel to get a complete biological picture of disease.

Related Content

Systems Biology: The Post Proteomics Era Begins?
The Search for Certainty: Trends in Early- and Late-Stage Dealmaking
Building Platforms in Orthopedics


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts